The Alliance of Community Health Plans (ACHP) appreciates the Administration’s willingness to engage industry partners regarding the recently FDA-approved Alzheimer’s drug, Aduhelm. ACHP shares concerns raised by many stakeholders regarding the lack of clinical evidence demonstrating value of the drug, use of beta-amalyloid plaques as a surrogate endpoint and patient safety. Below are recommendations ACHP submitted to the Centers for Medicare and Medicaid Services (CMS) as it considers coverage for Aduhelm.
Making Health Care Better
ACHP is the voice of a unique approach in health care today, one that puts the patient at the center with plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions, rooted in a model that is proven to deliver better value for patients, employers and taxpayers.